Data collected up to this point has provided sufficient follow-up and will allow for a reasonable estimate of the five-year survivorship rate for the Echo Bi-Metric Microplasty stem in primary total hip arthroplasty.

The primary objective of this study is to characterize survivorship of the Echo Bi-Metric Microplasty stem in unilateral or bilateral primary total hip arthroplasty at 5 years postoperative.

Primary objective

The primary objective of this study is to characterize survivorship of the Echo Bi-Metric Microplasty stem in unilateral or bilateral primary total hip arthroplasty at 5 years postoperative.

Secondary Objectives

Safety will be evaluated by monitoring the frequency and incidence of adverse events over time to 10 years postoperative.

Clinical, functional, radiographic, and quality of life outcomes will be assessed over time to 7 years postoperative. Clinical Outcomes will be measured using the Harris Hip Score and Physical Exam form. Radiographs will be reviewed to assess alignment, radiolucencies and other radiographic parameters. Health status and functional ability will be measured using the EQ-5D-3L and the UCLA Activity score.

Inclusion Criteria:

• Subjects are eligible for this trial if they satisfy all of the following criteria:

  • Patient is 18 to 65 years of age, inclusive
  • Patient is skeletally mature
  • Patient qualifies for primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:
  • Osteoarthritis
  • Avascular necrosis
  • Rheumatoid arthritis
  • Correction of functional deformity
  • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
  • Patient has no history of previous total hip arthroplasty or arthrodesis of the affected hip joint(s)
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent
  • Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB- approved informed consent

Exclusion Criteria:

• Subjects will be excluded from this trial if they satisfy any of the following criteria as determined by the research staff or in the judgment of the treating physician:

  • Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc.) in the affected hip joint(s)
  • Patient is septic or has an active infection
  • Patient is uncooperative patient or is incapable of following directions
  • Patient is diagnosed with osteoporosis
  • Patient is diagnosed with a metabolic disorder which may impair bone formation
  • Patient is diagnosed with osteomalacia
  • Patient has distant foci of infections which may spread to the implant site

The study population will comprise a cohort of a minimum of 200, and no more than 225, hips enrolled across up to 10 centers from subjects who require primary total hip arthroplasty. Subjects must be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will undergo an informed consent procedure, be required to sign an IRB-approved informed consent with required HIPAA authorization1, and eligibility will be determined based upon the inclusion/exclusion criteria.